17 décembre 2020 – EMA’s human medicines committee (CHMP) and its experts appear to be well on track to complete the evaluation of the data submitted by BioNTech and Pfizer in the context of the conditional marketing authorisation (CMA) application for BNT162b2, a COVID‑19 mRNA vaccine. Following receipt of additional data requested by the CHMP from the company and pending the outcome of its evaluation, an exceptional meeting of the CHMP has now been scheduled for 21 December to conclude if possible.

For further information, see here.